| abstract |
The present invention is directed to the creation of a pharmaceutical combination of a composition and methods comprising (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -5,6,7,8- tetrahydronaphthalen-2-ol or its pharmaceutically acceptable salt, parathyroid hormone or its biologically active fragment, methods of using such compositions and kits containing such compositions. These compositions are useful for treating musculoskeletal brittleness, including osteoporosis, osteoporotic fracture, bone loss, and brittleness. The international application was published along with an international search report. |